Multiple endocrine neoplasia, type II (MEN II).
D000293:Adolescent; D000310:Adrenal Gland Neoplasms; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D000368:Aged; D006631:Amine Oxidase (Copper-Containing) / Q000378:metabolism; D001842:Bone and Bones / Q000002:abnormalities; D002116:Calcitonin / Q000378:metabolism; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002869:Chromosome Aberrations / Q000175:diagnosis; D025063:Chromosome Disorders; D003480:Cushing Syndrome / Q000209:etiology; D004296:Dopa Decarboxylase / Q000378:metabolism; D005260:Female; D005729:Ganglioneuroma / Q000150:complications*; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology; D007413:Intestinal Mucosa; D008297:Male; D008382:Marfan Syndrome / Q000209:etiology; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary; D009463:Neuroma / Q000150:complications*; D010279:Parathyroid Diseases / Q000150:complications*; D010673:Pheochromocytoma; D011453:Prostaglandins / Q000032:analysis; D012701:Serotonin / Q000032:analysis; D013577:Syndrome; D013964:Thyroid Neoplasms; D014284:Triiodothyronine / Q000627:therapeutic use
D002272:Carcinoembryonic Antigen; D011453:Prostaglandins; D014284:Triiodothyronine; D012701:Serotonin; D000324:Adrenocorticotropic Hormone; D002116:Calcitonin; D006631:Amine Oxidase (Copper-Containing); D004296:Dopa Decarboxylase